Cancer Genetics Inc (NASDAQ:CGIX) Shorts Declined By 6.71%

April 20, 2018 - By Leslie Harms

Cancer Genetics, Inc. (NASDAQ:CGIX) Corporate Logo

During Q4 2017 the big money sentiment increased to 0.91. That’s change of 0.34, from 2017Q3’s 0.57. 4 investors sold all, 7 reduced holdings as Cancer Genetics, Inc. ratio increased. 7 grew positions while 3 funds amassed positions. Funds hold 2.78 million shares thus 7.43% more from 2017Q3’s 2.58 million shares.
67,677 are held by Two Sigma Lc. Macquarie Group Limited has invested 0% of its capital in Cancer Genetics, Inc. (NASDAQ:CGIX). Royal Retail Bank Of Canada stated it has 0% of its capital in Cancer Genetics, Inc. (NASDAQ:CGIX). 454 were reported by Barclays Plc. Hrt Lc invested in 0.04% or 23,199 shs. Geode Cap Mngmt Ltd Company invested in 87,279 shs. Wells Fargo Communication Mn stated it has 14,200 shs. Pennsylvania-based Vanguard Grp Inc has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Morgan Stanley has invested 0% of its capital in Cancer Genetics, Inc. (NASDAQ:CGIX). Jacobs Levy Equity Mngmt reported 16,489 shs stake. Northern Trust Corporation invested in 0% or 32,576 shs. National Bank Of America Corporation De reported 0% of its capital in Cancer Genetics, Inc. (NASDAQ:CGIX). Granahan Mngmt Ma holds 0.04% or 254,461 shs in its capital. 67,055 are owned by Diker Mngmt Ltd. Thompson Davis Com holds 500 shs.

Cancer Genetics, Inc. registered $24,339 net activity with 1 buy and 0 insider sales since December 15, 2017.

Cancer Genetics Inc (NASDAQ:CGIX) recorded a decrease of 6.71% in shorted shares. FINRA published in April CGIX’s total 368,500 shorted shares. Previously was reported down change of 6.71% from 395,000 shares. 2 days will cost CGIX With 162,500 average volume to recover its former position. 2.38% is Cancer Genetics Inc float short.

The stock decreased 2.44% or $0.03 during the last trading session, reaching $1.2.Cancer Genetics, Inc. has 1.30 million shares volume, 88.03% up from normal. CGIX is downtrending and has moved 66.34% since April 20, 2017. The stock underperformed the S&P500 by 77.89%.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China.The firm is worth $33.30 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.Last it reported negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

In total 2 analysts cover Cancer Genetics (NASDAQ:CGIX). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. 50% are bullish. With $6.0 highest and $6.0 lowest [Target] Cancer Genetics has $6 average [Target] or 400.00% above the current ($1.2) price. 5 are the (NASDAQ:CGIX)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. On Tuesday, February 6 the firm has “Buy” rating given by H.C. Wainwright. On Tuesday, April 3 Maxim Group downgraded the shares of CGIX in report to “Hold” rating. The company rating was maintained by H.C. Wainwright on Wednesday, November 29. On Tuesday, January 16 the stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given by H.C. Wainwright. On Thursday, December 7 the stock of Cancer Genetics, Inc. (NASDAQ:CGIX) earned “Buy” rating by Maxim Group.

Cancer Genetics, Inc. (NASDAQ:CGIX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.